Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR(R) artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. To view the full press release, visit https://ibn.fm/LRGUo.
This patent allowance is significant because it strengthens Lantern Pharma's position in precision oncology by protecting a method to identify patients most likely to respond to LP-184, potentially improving clinical outcomes and reducing unnecessary treatments. The biomarker signature, discovered through the RADR platform, exemplifies how artificial intelligence can streamline drug development and personalized medicine. The 45% disease control rate in Phase 1a provides early evidence of efficacy, and the planned Phase 1b/2 studies will further evaluate LP-184 in biomarker-selected patient populations.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. The company's pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics. Additionally, Lantern offers withZeta.ai, a commercially available multi-agentic AI co-scientist platform. More information is available in the company's newsroom at https://ibn.fm/LTRN.
The patent allowance underscores the importance of biomarker-driven approaches in oncology, potentially setting a precedent for how AI can identify predictive biomarkers. As Lantern Pharma advances LP-184, this intellectual property could provide a competitive edge and attract partnerships. The company's focus on hard-to-treat cancers like ovarian and liver cancer addresses significant unmet medical needs, and the precision medicine strategy may lead to more effective therapies with fewer side effects.
